International collaborative study on the 3rd WHO International Standard for hepatitis B surface antigen  by Wilkinson, Dianna E. et al.
I
S
D
D
L
a
b
S
c
d
a
A
R
R
A
K
W
H
H
A
1
(
o
I
i
l
h
1
nJournal of Clinical Virology 82 (2016) 173–180
Contents lists available at ScienceDirect
Journal  of  Clinical  Virology
jou rn al hom epage: www.elsev ier .com/ locate / j cv
nternational  collaborative  study  on  the  3rd  WHO  International
tandard  for  hepatitis  B  surface  antigen
ianna  E.  Wilkinsona,∗, Pia  L.  Seizb,  Christian  G.  Schüttlerb, Wolfram  H.  Gerlichb,1,
ieter  Glebeb,  Heinrich  Scheiblauerc, Sigrid  Nickc, Michael  Chudyc,  Thomas  Dougalld,
indsay  Stonea,  Alan  B.  Heathd,1, the  Collaborative  Study  Group2
Division of Virology, South Mimms, Potters Bar, Herts., EN6 3QG, UK
Institute of Medical Virology, Justus-Liebig University Giessen, National Reference Center for Hepatitis B and D Viruses, Biomedical Research Center
eltersberg, Schubertstr. 81, 35392 Giessen, Germany
Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, D 63225 Langen, Germany
Biostatistics National Institute for Biological Standards and Control, South Mimms, Potters Bar, Herts., EN6 3QG, UK
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 26 February 2016
eceived in revised form 31 May  2016
ccepted 3 June 2016
eywords:
HO  international standard
BsAg
BV diagnostics
ssay standardization
a  b  s  t  r  a  c  t
Background:  The  WHO  International  Standard  (IS)  for  hepatitis  B  surface  antigen  (HBsAg)  is  used  to
standardize  HBsAg  assays.  Stocks  of  the  2nd  IS  for  HBsAg  are  depleted.  The  proposal  to  establish  its
replacement  was  endorsed  by  WHO  in  2012.
Objective: Preparation  of  a freeze-dried  candidate  3rd IS (NIBSC 12/226);  evaluation  of  its suitability  in a
WHO international  collaborative  study;  calibration  of  its potency  in  International  Units  (IU).
Study  design:  The  3rd  IS  is based  on plasma-derived,  puriﬁed,  inactivated  HBsAg  from  Vietnam.  Qualitative
and quantitative  HBsAg  assays  were  used  to  evaluate  12/226  alongside  the  2nd  IS  and 1st IS. Blinded  study
samples  included  a duplicate  of  12/226,  a  negative  control  and  two diluted  plasma  samples  representing
hepatitis  B virus  (HBV)  genotypes  A and  B.
Results:  Twelve  laboratories  from  9  countries  returned  22 data  sets  from  15 methods.  The  overall  geomet-
ric mean  potency  of  12/226  is 47.3  IU/mL  (±13%  CV)  when  compared  to the  2nd IS  with  HBV  subgenotype
A2.  The  3rd  IS has  HBV  subgenotype  B4  with  a heterogeneous  HBsAg  subtype  population  of  ayw1  and
adw2.  Some  genotype-dependent  effects  on  the  inter-laboratory  variability  were  observed  but  over-
all  mean  potencies  were  virtually  identical  irrespective  of  the IS  used  for calibration.  Stability  studies
indicate  that  the candidate  is stable  for long-term  use.
Conclusions:  12/226  was  established  in October  2014  by  the  WHO  Expert  Committee  on  Biological  Stan-
dardization  as  the 3rd IS  for  HBsAg  with  a potency  of 47.3  IU  per  ampoule  maintaining  the  continuity  in
the  standardization  of  HBsAg  assays.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Background
The WHO  Expert Committee on Biological Standardization
ECBS) establishes International Standards (IS) as the highest order
f references for biological substances with potencies assigned in
nternational Units (IU) [1]. The WHO  IS for HBsAg is used for val-
dation of HBsAg assays by clinical laboratories, blood transfusion
aboratories, manufacturers of blood products and manufacturers
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386-6532/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u
d/4.0/).of in vitro diagnostic kits and to calibrate secondary reference
materials for HBsAg. The 2nd IS is now depleted and the ECBS
endorsed its replacement in October 2012. This report describes
the development and worldwide evaluation of the 3rd WHO  IS for
HBsAg.
2. Objectives
Assess the suitability of a freeze-dried formulation to serve as
3rd IS; calibrate the candidate relative to the 2nd IS in IU per
ampoule; assess the candidate’s potency in assays performed in
different laboratories; assess the commutability of the candidate to
serve as a standard for different sample types; evaluate its stability.
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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Table 1
Collaborative study samples.
Sample Code Sample Name Description Presentation
12/226 Candidate 3rd WHO  IS for
HBsAg
Non-adjuvanted plasma-derived HBsAg
vaccine bulk. HBV genotype B4, HBsAg
subtypes ayw1/adw2 formulated to ∼50 IU/mL.
Freeze-dried
Ampoule
00/588 NIBSC 00/588 2nd WHO  IS for HBsAg genotype A2 subtype
adw2 (33 IU/mL) [3,4]
Freeze-dried
Vial
80/549 NIBSC 80/549 1st WHO  IS for HBsAg subtype group ad
(100 IU/mL) [5,6]
Freeze-dried
Vial
sample A NIBSC 01/402 Blinded reference panel member inactivated
HBsAg genotype A2 subtype adw2 (∼2 IU/mL)
[3]
Freeze-dried
Vial
sample B NIBSC 00/616 Blinded negative reference panel member
consisting of normal re-calciﬁed plasma [3]
Freeze-dried
Vial
sample C NIBSC 12/226 Blinded duplicate candidate 3rd WHO  IS for
HBsAg
Freeze-dried
Ampoule
sample D aPEI Sample N4222 Blinded HBV genotype B2 HBsAg subtype adw2
[10]
Unitage not assigned
Pre-diluted to a target 79 IU/mL
Liquid
Screw-capped tube
sample E aPEI sample N4879 Blinded HBV genotype A2 HBsAg subtype adw2
[10]
Unitage not assigned
Pre-diluted to a target 74 IU/mL
Liquid
Screw-capped tube
of me
a
3
3
(
w
H
t
P
D
t
d
w
w
w
p
u
c
1
E
3
[
i
n
r
3
p
p
s
m
pa The PEI Samples are the unprocessed source materials used in the preparation 
ssays  (PEI product code 6100/09) [10].
. Study design
.1. Candidate material
The source material is a plasma-derived HBsAg vaccine bulk
lot HB-PL01) without adjuvant (VABIOTECH, Vietnam). The plasma
as obtained from asymptomatic carriers with high viremia. The
BsAg was puriﬁed and inactivated using validated methods for
he manufacture of plasma-derived hepatitis B vaccines [2]. HB-
L01 was found positive for HBV DNA and the sequence of the HBV
NA showed two different wildtype strains, both with subgeno-
ype B4 and HBsAg subtype ayw1 or adw2 (Seiz et al., doi: http://
x.doi.org/10.1016/j.jcv.2016.05.009).
Based on a preliminary mean potency of 36,450 IU/mL, the bulk
as adjusted to ∼50 IU/mL in thrombinized and declotted plasma
hich was negative for HIV, HCV and HBV viral markers. Bronidox
as included as preservative at 0.05%. The formulation was pre-
ared and ﬁlled into ampoules in 1 mL  aliquots and freeze-dried
sing standard operating procedures. The material is NIBSC product
ode 12/226.
The target concentration and the detection limit of HBsAg of
2/226 were conﬁrmed by the IVD Test Laboratory at the Paul-
hrlich-Institut (PEI), Germany.
.2. Additional study samples
The 2nd IS (NIBSC 00/588) [3,4] and the 1st IS (NIBSC 80/549)
5,6] were included in the study un-blinded. Blinded samples
ncluded a duplicate of 12/226, a diluted version of the 2nd IS, a
egative control and two diluted non-inactivated plasma samples
epresenting HBV subgenotypes A2 and B2 (Table 1).
.3. Collaborative study
Participating laboratories are listed in Table 2. For each method,
articipants were requested to perform 3 assays using fresh sam-
les each time, to test 2 independent dilution series of the study
amples and assay all samples concurrently. Codes for the assay
ethods used are summarized in Table 3. Raw data for each dilution
oint were reported in Excel spreadsheets.mbers of the 1 st WHO  International Reference Panel for HBV genotypes for HBsAg
3.4. Statistical methods
All laboratories are referred to by code number not representing
the order of listing in Table 2. Where a laboratory returned data
using different assay methods, the results were assessed separately
for each method and are referred to according to the lab number
and assay code e.g. 3 Eql and 3 Mv3.
Individual assays were analyzed as multiple parallel-line assays
using CombiStats [7] and expressing the potency of the study sam-
ples relative to the different references. All study samples were
included in the analysis of each assay. A log transformation of each
response and subtraction of the assay’s average blank, if applica-
ble, were used to achieve linearity and parallelism. Where assays
were spread over different plates, the data from individual plates
were analyzed independently, where the relevant reference was
included on the plate. Potency estimates were then combined
across plates, to give single estimated potencies for each sample
for each assay.
Potency estimates were combined using unweighted geomet-
ric means (GM), to give laboratory mean potency estimates for the
study samples against the appropriate reference. Overall means for
the study were calculated as unweighted geometric means of the
individual laboratory means. Variability within (intra-laboratory)
and between (inter-laboratory) laboratories was expressed as a
geometric coefﬁcient of variation (% GCV) [8].
Differences in potency estimates between different methods
were assessed using a multiple comparison Analysis of Variance
with Tukey’s correction for multiple comparisons [9].
3.5. Stability studies
3.5.1. Accelerated degradation
Ampoules were stored at indicated temperatures, then removed
after 343 days and held at −80◦ C until assayed. Freshly reconsti-
tuted ampoules were tested concurrently in 3 independent assays
using method Mv3. The potencies of the samples were calculated
relative to the sample stored at −70◦ C. The long-term stability of
12/226 was  assessed using the Arrhenius model for accelerated
degradation studies using weighted and semi-weighted data [9].
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Table  2
Collaborative study participants. (In alphabetical order by country).
Name Laboratory Country
T McDonald National Reference Laborarory, Fitzroy Australia
V  Lievre L’Agence nationale de sécurité du médicament et des produits de santé − ANSM, Saint-Denis cedex France
R  Bäeuerlein and I Krüger Roche Diagnostics GmbH, Penzberg Germany
H  Scheiblauer and S Nick Testing Laboratory for in-vitro Diagnostic Medical Devices at the Paul-Ehrlich-Institut (PEI-IVD), Langen Germany
R  Chhabra Immuno Diagnostic Kit Laboratory, National Institute of Biologicals, Ministry of Health and Family Welfare, NOIDA India
L.  Pallavicini andM. DeLuca DiaSorin SpA, Saluggia (VC) Italy
G  Pisani and F Marino Biologicals Unit, National Center for Immunobiologicals Research and Evaluation (CRIVIB), Istituto Superiore di Sanita, Rome Italy
K  Ishii National Institute of Infectious Disease, Dept. of Virology II, Tokyo Japan
C  Morris National Institute for Biological Standards and Control − NIBSC, South Mimms UK
F  Kori U.S. Food and Drug Administration-FDA/CBER/OCBQ/DBSQC/LACBRP, Kensington USA
M  Kuhns Abbott Diagnostics Division, Abbott Park USA
N  Thu Van VABIOTECH, Ha Noi Vietnam
Table 3
Collaborative study assay methods and codes.
Quantitative automated assays
Assay Code Assay No. of data sets
Aqn  ARCHITECT HBsAg, Abbott Diagnostics 2
Eqn  Elecsys HBsAg II, Roche Diagnostics 2
LxL  LIAISON XL murex HBsAg Quant, Diasorin S.p.A. 1
Qualitative automated assays
Assay Code Assay No. of data sets
ADq  ADVIA Centaur HBsAg, Siemens Healthcare Diagnostics Inc. 1
Aql ARCHITECT HBsAg Qualitative II, Abbott Diagnostics 1
Eql  Elecsys HBsAg II, Roche Diagnostics 2
LDi  LIAISON HBsAg, Diasorin S.p.A. 1
PRq  PRISM HBsAg, Abbott Diagnostics 3
VBi  VIDAS HBsAg ULTRA ELFA, BioMérieux 1
Qualitative semi-automated/manual assays
Assay Code Assay No. of data sets
En6  Enzygnost HBsAg 6.0,Siemens Healthcare Diagnostics Products GmbH 1 manual1 semi-automated
DPr  HBsAg one, Dia. Pro 1
HeB  Hepanostika HBsAg Ultra, BioMérieux 1
MiS  Microscreen HBsAg ELISA, Span Diagnostics 1
Mv3  Murex HBsAg Version 3, Diasorin Ltd./S.p.A UK Branch 1 manual1 semi-automated
SD3  SD HBsAg ELISA 3.0, Standard Diagnostics 1
Table 4
Thermal degradation assessment of 12/226 stored for ∼1 year at the indicated temperatures. Potencies are expressed relative to the material stored at −70 ◦C (assigned a
unitage  of 1 for the purpose of this assessment). The % loss per month or year was  predicted using the Arrhenius modela.
Temperature (◦C) Assay Potency Combined Potency Predicted % Monthly Loss Predicted % Yearly Loss
1 1.00
−20 2 1.12 1.05 < 0.01 < 0.01
3  0.99
1  1.02
+4 2 1.04 1.02 < 0.01 0.03
3  1.00
1  1.00
+20 2 0.99 0.99 0.07 0.84
3  0.89
1  0.89
+37 2 0.75 0.78 2.00 21.52
3  0.73
1  0.33
+45 2 0.38 0.35 NC NC
3  0.40
+56b NT
Abbreviation: NC = not calculated. NT = not tested.
a The predictions are dependent on the estimated potencies at +37 ◦C and above being reliable, and the apparent drop in potency not being affected by problems of
r entage
t t degr
3
teconstitution. This was  seen with +45 ◦C and the sample cannot be assigned a perc
o  obtain reliable predictions from the data for +4 ◦C and +20 ◦C alone, as insufﬁcien
b The ampoules stored at 56◦ C could not be reconstituted..5.2. Stability after reconstitution
Ampoules stored as described above for accelerated degrada-
ion, were reconstituted and the samples returned to storage at predicted loss due to the difﬁculty in reconstituting the material. It is not possible
adation has occurred.+4 ◦C for 2 months. Potencies of the stored reconstituted samples
were determined relative to a freshly reconstituted sample that had
been stored continuously at −70◦ C.
176 D.E. Wilkinson et al. / Journal of Clinical Virology 82 (2016) 173–180
Table 5
Potencies (IU/mL) relative to 2nd IS.
Study Sample 1st IS
sgt A2
(100 IU/mL)
Sample A inactivated
sgt  A2 (01/402)
(∼2  IU/mL)
Sample E sgt A2
(PEI  N4879)
(∼74 IU/mL)
Candidate 3rd IS sgt
B4  (12/226)
(∼50 IU/mL)
Sample C
duplicate 3rd IS
(∼50  IU/mL)
Sample D sgt
B2  (PEI N4222)
(∼79 IU/mL)
Sample B
(00/616)
Negative
Lab N GM GVC N GM GCV N GM GCV N GM GCV N GM GCV N GM GCV N GM
1 VBi 3 168.9 2.4 3 2.25 1.5 3 138.3 0.5 3 56.0 1.7 3 53.5 1.3 3 90.4 2.0 3 ND
2  PRq 3 82.5 7.8 3 1.76 0.9 3 100.5 3.0 3 45.2 5.9 3 45.2 2.6 3 73.5 4.8 3 ND
3  Eql 3 97.2 6.3 3 1.84 8.5 3 96.4 3.0 3 43.9 2.5 3 45.0 1.5 3 73.1 3.3 3 ND
3  Mv3 3 132.7 10.0 3 1.72 11.9 3 105.4 15.7 3 53.4 6.8 3 47.4 14.9 3 60.0 8.7 3 ND
4  LDi 3 132.3 8.4 3 1.80 6.7 3 165.3 2.1 3 42.3 4.7 3 45.5 7.5 3 103.6 6.5 3 ND
4  LxL 3 91.0 2.7 3 2.02 7.6 3 138.0 5.2 3 62.2 6.2 3 62.0 8.1 3 99.1 0.7 3 ND
5  Eqn 9 104.9 4.2 9 1.84 5.2 9 118.1 2.8 9 42.0 2.3 9 41.1 2.8 9 71.2 3.6 9 ND
6  Eql 3 95.5 10.9 2 1.44 21.2 3 89.3 12.3 3 45.3 3.9 3 39.0 17.1 3 75.8 22.9 3 ND
7  Aql 3 74.5 1.8 3 1.77 1.3 3 103.1 9.5 3 63.2 1.8 3 61.7 1.3 3 122.4 1.9 3 ND
7  Aqn 3 86.5 2.8 3 1.72 7.3 3 107.9 4.8 3 48.5 5.0 3 47.0 5.0 3 80.0 2.1 3 ND
7  PRq 3 97.7 4.7 3 1.87 5.1 3 119.7 4.3 3 49.8 3.8 3 49.1 2.6 3 84.6 4.1 3 ND
8  HeB 1 116.2 NA 1 1.45 NA 1 128.8 NA 1 50.6 NA 1 38.1 NA 0 NT NA 1 ND
8  MiS 0 IV NA 0 1.90 NA 0 NT NA 1 47.7 NA 1 47.5 NA 1 127.2 NA 1 ND
8  SD3 0 IV NA 0 IV NA 1 a NA 0 IV NA 1 a NA 0 NT NA 1 ND
9  Mv3 4 118.6 11.5 4 2.05 10.5 4 66.2 11.2 4 62.6 7.3 4 48.7 6.5 4 70.1 5.3 4 ND
10  ADq 3 66.7 0.2 3 1.88 3.0 3 75.5 3.0 3 43.7 1.3 3 41.4 4.2 3 72.2 2.6 2 ND
10  Aqn 3 91.4 0.7 3 1.84 7.8 3 69.0 4.5 3 49.3 8.4 3 46.3 5.0 3 69.4 2.3 3 ND
10  Eqn 3 93.9 2.3 3 1.90 3.2 3 81.9 4.8 3 43.8 1.9 3 42.0 3.3 3 69.1 3.2 0 NT
10  En6 3 115.5 5.7 2 1.98 4.5 3 90.2 1.4 3 43.4 6.6 3 41.2 6.9 3 62.2 1.3 0 NT
10  PRq 3 88.3 5.9 0 IV NA 0 NT NA 3 50.6 3.7 3 42.0 6.5 0 NT NA 2 ND
11  En6 3 120.4 4.2 3 1.90 2.9 3 120.6 10.0 3 39.5 4.4 3 39.5 5.8 3 69.0 4.2 3 ND
12  DPr 1 57.9 NA 1 1.73 NA 3 145.6 7.4 3 46.1 11.5 1 57.1 NA 1 101.1 NA 3 ND
overall  GM 98.7 1.8 105.2 48.6 46.2 80.9 NA
%  GCV 28 11 29 15 15 24 NA
Abbreviations;: sgt = subgenotype; GM = Geometric mean; %GCV = Geometric coefﬁcient of variation; ND = not detected; NA = not applicable; NT = assay not performed;
IV  = invalid.
a Discrepant values from a single assay were not included in calculation of overall GM and overall %GCV.
Table 6
Overall mean estimates (IU/mL) for potency and inter-laboratory variability (%GCV) for samples A, C, D and E relative to the 2nd IS, the candidate 3rd IS or the 1st IS.
Reference 2nd IS (33 IU/mL)
sgt A2
Candidate 3rd IS
(50 IU/mL) sgt B4
1st IS (100 IU/mL)
sgt A2 (plasma)
Sample No. ofassays Overall GM Overall% GCV Overall GM Overall% GCV Overall GM Overall% GCV
Code sgt Type
A A2 2nd IS 56 1.8 11 1.9 18 1.9 29
C  B4 3rd IS 63 46.2 15 47.2 10 46.8 37
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E  A2 plasma 63 105.2 29 
bbreviations: sgt: subgenotype; GM = Geometric mean; %GCV = Geometric coefﬁci
.5.3. Stability after freeze-thaw
Ampoules stored at −20◦ C were reconstituted and then sub-
ected to freeze-thaw cycles. Potencies of the freeze-thawed
amples were determined relative to a freshly reconstituted sample
hat has been stored continuously at −70◦ C.
. Results
.1. Production, validation and stability assessment of 12/226
The product summary for 12/226 is shown in Supplemen-
al Table 1. Validation assessment performed at PEI indicated
hat the potency (50 IU/mL, 31% GCV) and analytical sensitivity
0.016–0.029 IU/mL) for 12/226 (Supplemental Tables 2 and 3) were
cceptable and that the candidate was suitable for evaluation in the
nternational collaborative study.
The long-term stability of 12/226 was predicted using the Arrhe-
ius model (Table 4). The predicted percentage potency loss, at
he different temperatures of storage, indicates that 12/226 is
dequately stable to serve as IS, and is suitable for ambient trans-
ortation as the loss at 37 ◦C is only 2% after 1 month.
Additional potency estimates were determined for the degrada-
ion samples to evaluate the stability of 12/226 after reconstitution
nd subsequent storage at +4 ◦C for 2 months (Supplemental Table
). For temperatures up to 37 ◦C, there was no signiﬁcant differ-
nce in potency found for any of the temperature points stored in
he freeze-dried state for 1 year compared to storage at +4 ◦C for83.1 23 80.2 44
107.9 34 106.2 39
 variation.
2 months after reconstitution. Additional assessment of reconsti-
tuted and refrozen samples of 12/226 showed no signiﬁcant loss of
potency for up to 3 freeze-thaw cycles compared to freshly recon-
stituted samples (Supplemental Table 5).
4.2. Collaborative study
4.2.1. Data received
Twelve laboratories submitted 22 data sets for 15 qualita-
tive and quantitative assay methods. Five participants performed
more than one method. The majority of laboratories returned the
requested three assays with each method that they used. Labo-
ratory 8 only performed one assay with each of three different
methods. The results for method 8SD3 for 12/226, the 1st IS and
sample A were invalid due to non-parallelism/non-linearity. For
sample C, the result obtained by 8SD3 was  much higher than all
other laboratories and methods, including results reported by lab-
oratory 8 with different assay methods. The data were only from
a single assay and because of this discrepancy; the results from
8SD3 were excluded from the calculations of overall GM and %GCV.
Laboratory 12 used multiple plates per assay so not all samples
comparisons could be made against the different references for
each assay.4.2.3. Potencies
The individual laboratory GM potencies expressed relative to
the 2nd IS along with the intra-laboratory % GCVs are shown in
Table 5 for the 1st IS, 12/226 and samples A-E (Supplemental sta-
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Fig. 1. Relative potencies of sample A (diluted 2nd IS) against the (a) 2nd IS, (b)
candidate 3rd IS and (c) 1st IS. Each box in the histogram represents the labora-
tory geometric mean potency (log10 IU/mL) for a particular assay method, and is
labelled with the laboratory and method code. Automated quantitative assays are
represented by the dark grey boxes. Manual and automated qualitative assays are
represented by the light grey and white boxes, respectively.
Fig. 2. Relative potencies of sample C (duplicate 3rd IS) against the (a) 2nd IS, (b)
candidate 3rd IS and (c) 1st IS. Each box in the histogram represents the labora-
tory  geometric mean potency (log10 IU/mL) for a particular assay method, and is
labelled with the laboratory and method code. Automated quantitative assays are
represented by the dark grey boxes. Manual and automated qualitative assays are
represented by the light grey and white boxes, respectively.
tistical methods). For each sample, the overall GM potency across
laboratories is also shown, along with the inter-laboratory % GCV.
No false positives were found with the negative control (Sam-
ple B). The overall GM potency of the 1st IS (98.7 IU/mL) was in
excellent agreement with its assigned potency of 100 IU/mL. The
inter-laboratory agreement for the 1 st IS (28% GCV) is close to
results determined in the collaborative study that established the
2nd IS (30% GCV) [3]. These results indicate that the continuity of
the 2nd IS with respect to the 1st IS had been maintained since its
establishment in 2003.
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The potency of 12/226 (48.6 IU/mL) and its duplicate sample C
46.2 IU/mL) is close to the target 50 IU/mL. The difference between
he potency of 12/226 and sample C is not statistically signiﬁ-
ant and combining the data across the two samples gives a mean
otency of 47.3 IU/mL (Supplemental statistical methods and Sup-
lemental Table 6).
.2.3. Intra-laboratory and inter-laboratory variability
The individual laboratory%GCVs for potencies expressed rela-
ive to the 2nd IS are shown for the study samples in Table 5 and
upplemental Table 6. Generally, laboratories show a good level
f reproducibility for each method. For 12/226 and its duplicate
ample C, the majority of laboratories have a%GCV below 8%, with
he highest%GCV at 17.1%. Comparing the%GCV values, the inter-
aboratory variability generally is greater than the intra-laboratory
ariability. There is, however, an improvement in inter-laboratory
ariability for 12/226 (15% GCV) with respect to the 1 st IS which
ives a higher%GCV of 28% (Table 5). The candidate plus sample
 against the 2nd IS shows similar levels of inter-laboratory vari-
bility giving a combined overall%GCV of 13% (Supplemental Table
).
The overall mean potencies of samples A, C, D and E relative
o the 2nd IS, 12/226 and the 1st IS are shown in Table 6 along
ith the inter-laboratory%GCVs. The results are also shown in
istogram form in Figs. 1–4 . Assays of these samples give inter-
aboratory%GCVs in the range of 11%–44%, which is consistent
ith inter-laboratory variability reported for similar collaborative
tudies [3,10]. There were no signiﬁcant differences in potency esti-
ates between quantitative and qualitative methods (Figs. 1–4).
The best inter-laboratory agreement is obtained when the
otency of a sample is expressed relative to a reference that is
ost like itself. For example, sample A is a dilution of the same
nactivated bulk used to prepare the 2nd IS. The inter-laboratory
ariability for sample A, is lowest when potency is expressed rel-
tive to the 2nd IS, giving a%GCV of 11%. The inter-laboratory
ariability is somewhat increased (18% GCV), when potencies for
ample A are expressed relative to 12/226 (B4 ayw1/adw2) which,
ike the 2nd IS, is derived from puriﬁed and heat-inactivated HBsAg.) candidate 3rd IS and (c) 1st IS. Each box in the histogram represents the laboratory
h the laboratory and method code. Automated quantitative assays are represented
light grey and white boxes, respectively.
However, calibration with the 1st IS, which is derived from diluted
native HBsAg-containing plasma, gives a higher variability (29%
GCV) even though it has the same HBV subgenotype (Table 6 and
Fig. 1).
Similarly, inter-laboratory variability of sample C is lowest
when potencies are expressed relative to its duplicate, 12/226 (10%
GCV). When expressed against the 2nd IS or the 1st IS, the inter-
laboratory%GCV for sample C increases to 15% and 37%, respectively
(Table 6 and Fig. 2).
The inter-laboratory%GCV values for Sample D (B2 adw2) rel-
ative to the 2nd IS, 12/226 or 1st IS are 24%, 23% and 44%,
respectively. For sample E (A2 adw2), the inter-laboratory%GCVs
are 29%, 34% and 39% respectively (Table 6 and Figs. 3–4). While
the variability between laboratories is greatest for these samples,
the overall%GCVs for samples D and E is typical for current HBsAg
assays [10].
5. Discussion
Candidate 3rd WHO  IS for HBsAg (NIBSC 12/226) is a batch of
3200 ampoules containing 1.0 mL freeze-dried HBsAg formulated
in thrombinized and declotted plasma. The material used to pro-
duce 12/226 is a soluble inactivated HBsAg vaccine bulk puriﬁed
from human plasma obtained from viremic carriers. Biosafety is
the rationale for using HBsAg derived from a vaccine in that ideally
the IS should not contain infectious HBV. This is the case for 12/226
and the 2nd IS.
The IS should also be representative for a region with high HBV
prevalence. The HBV B4 genotype of 12/226 is highly prevalent in
Vietnam [11], whereas the HBV A2 genotype of the 1 st and 2nd ISs
is prevalent in Europe and the USA. Because multiple donors were
used for preparing the bulk, 12/226 is heterogeneous containing
HBV strains encoding subtypes ayw1 and adw2 (Seiz et al. accepted).
When calibrated against the 2nd IS, 12/226 has an overall geo-
metric mean potency of 47.3 IU/mL, a value close to the intended
target of 50 IU/mL (Table 6).
The extent to which a reference is suitable to serve as a standard
for the variety of test samples being assayed, i.e. its commutabil-
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Wig. 4. Relative potencies of sample E (diluted plasma with sgt A2) against the (a) 2nd
eometric mean potency (log10 IU/mL) for a particular assay method, and is labelle
y  the dark grey boxes. Manual and automated qualitative assays are represented b
ty, is determined by many factors including methods of reference
reparation such as puriﬁcation, inactivation and freeze-drying
teps; the sample matrix (e.g. native plasma or serum); and molec-
lar and antigenic variants of the analyte (e.g. differences in HBs
rotein composition, genotype or vaccine escape mutants). An
spect of commutability was addressed in this study by including
amples representing different HBV genotypes. The HBV subgeno-
ype is an important factor contributing to the variability of HBsAg
ssays [3,10] and, some (sub)genotype-dependent effects on the
nter-laboratory variability were observed (Table 6 and Figs. 1–4);
owever, the inter-laboratory%GCV obtained in this collaborative
tudy, indicate that the performance of 12/226 is comparable to
hat of the 2nd WHO  IS in harmonising HBsAg assays. The observed
nter-laboratory variability may  thus be related to design differ-
nces between assay methods. Ideally, assays should be able to
etect all known HBV genotypes equally well, however the meth-
ds of antigen capture and detection contribute to assay sensitivity
nd speciﬁcity. Fifteen of the 22 data sets represent different assay
ethods and thus inter-assay variability can be inferred from the
nter-laboratory variability. The study on the WHO  HBsAg genotype
anel identiﬁed also some HBsAg assays which performed differ-
ntly with the inactivated IS and native plasma samples of the same
ubgenotype [10]. Taken together the data of Tables 5 and 6 and
igs. 1–4 suggest that the nature of the sample − HBsAg positive
lasma or puriﬁed and inactivated HBsAg − creates larger differ-
nces between different methods than the HBV genotype or HBsAg
ubtype. Irrespective of the detectable differences between differ-
nt methods, all samples yielded virtually identical overall GM with
he three ISs (Table 6). In addition, the overall%GCVs for samples
xpressed against 12/226 are in line with overall%GCVs observed
n similar studies [3,10].
Along with the WHO  HBV genotype panel for HBsAg assays
PEI product 6100/09) [10] and the WHO  reference panel (NIBSC
3/262) [3], the use of 12/226 as calibrator, will facilitate the char-
cterization and standardization of the factors that contribute to
ssay sensitivity and variability and assist in the development of
niform management strategies for HBV-associated disease.
Stability studies indicate that 12/226 is stable for long-term
torage at −20 ◦C as well as for short-term storage at +4 ◦C and
hipment at ambient temperatures. After reconstitution 12/226
◦ay  be stored at +4 C for up to 2 months or may  undergo up to
 freeze-thaw cycles with no signiﬁcant loss of potency.
In October 2014, the WHO  ECBS established 12/226 as the 3rd
HO IS for HBsAg (HBV genotype B4, HBsAg subtypes ayw1/adw2)) candidate 3rd IS and (c) 1st IS. Each box in the histogram represents the laboratory
h the laboratory and method code. Automated quantitative assays are represented
light grey and white boxes, respectively.
with a potency of 47.3 IU/mL when reconstituted as directed in the
instructions for use. The 3rd IS for HBsAg is available from NIBSC
(http://www.nibsc.org/). It is intended to be used by laboratories
to calibrate secondary reference materials for HBsAg and in the
determination of analytical sensitivity of HBsAg assays.
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